. Exogenous Eptastigmine -Phosphotriesterase Combination in DFP In-AChE, BChE, and CaE provide alternative binding sites for toxication. TUOVINEN, K., KALISTE-KORHONEN, E., RAUSHEL, OPs and reduce the inhibition of endogenous body enzymes. amount of OP in the body and prevents the inhibition of A novel therapy against organophosphate exposure, the combi-body esterases.
The aim of the present study was to investigate whether a ity returned 24 hr later to normal in eptastigmine-phosphotries-combination of carbamate-phosphotriesterase could protect terase-treated groups. With phosphotriesterase only, it recovered body ChEs against DFP better than phosphotriesterase alone. inhibit the esterases. The carbamate used was eptastigmine, a new compound with lower toxicity and a longer duration of action at ChEs than physostigmine. Furthermore, the efSeveral different approaches have been tried in the therapy fects of eptastigmine and physostigmine on body esterases of organophosphate (OP) poisoning. Oximes like 2-PAM, and behavior of the animals were compared. toxogonin, and HI-6 can actively reactivate the OP-inhibited cholinesterases (ChEs). Carbamates like physostigmine reversibly inhibit the ChEs and thus prevent access and subse-
MATERIALS AND METHODS
quent binding of OPs to the active site (Somani and Dube, 1989) . A potentially novel alternative to OP antidotes is the Chemicals and Materials use of exogenous enzymes such as purified acetylcholines-
The derivative of physostigmine (molecular weight 275), heptylphysosterase (AChE) (Ashani et al., 1991; Wolfe et al., 1987, tigmine (eptastigmine; MF-201 tartrate; molecular weight 359), was pur-1991), butyrylcholinesterase (BChE) (Ashani et al., 1991; chased from Mediolanum (Milano, Italy) and physostigmine from Sigma Broomfield et al., 1991) , carboxylesterase (CaE) (Maxwell, Chemical Company (St. Louis, MO) . Both carbamates were dissolved in 0.9% NaCl (saline) solution. The phosphotriesterase enzyme was dissolved 1992), or OP hydrolases Kaliste-Korho- in 50 mM Hepes buffer, pH 8.5, 1.0 mg/ml with 12,000 U/ml (12,000 U/mg prot.) of paraoxon hydrolyzing activity. and a protein preparation was purified by Omburo et al. (1992) at Texas substrate. The kinetics of the enzyme reaction was spectrophotometrically followed at 400 nm at 22ЊC. A&M University. DFP was purchased from Fluka AG (Buchs, Switzerland), and it was dissolved in olive oil. Substrates such as acetylthiocholine, butyrylthiocholine and propionylthiocholine iodide, bovine albumin, atro-Assay of Plasma Paraoxon Hydrolyzing Activity pine sulfate, 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB), 4,4-dithiopyridine Paraoxon hydrolyzing activity of phosphotriesterase was measured from (PDS), and Triton X-100 were purchased from Sigma Chemical Company. plasma using paraoxon as the substrate as described by Tuovinen et al. Paraoxon (diethyl-p-nitrophenylphosphate) , the substrate of paraoxonase, (1994) . The activity was spectrophotometrically monitored at 405 nm was purchased from Ehrenstorfer (Augsburg, Germany). Astra 1397-HCl at 37ЊC. (10-diethylaminopropionyl phenothiazine-HCl), the specific inhibitor for BChE, was purchased from Astra (Södertälje, Sweden).
Protein Animals
Protein levels were determined according to Lowry et al. (1951) , using The animals used were 11-week old CD 2 F 1 male mice (26-30 g) (Na-bovine serum albumin as a standard. tional Laboratory Animal Center, Kuopio, Finland). They were housed in groups of six animals in stainless steel cages with aspen bedding (Tapvei Statistical Analysis Co., Kaavi, Finland). The mice were housed in a controlled environment: temperature 22 { 1ЊC, the relative humidity 50 { 10%, and light period of
The enzymatic data are presented as means { SD. Comparison of enzyme 12 hr (07.00-19.00). Pellets of mouse diet (R36, Lactamin AB, Södertälje, activities between groups was calculated using one way analysis of Sweden) and water were freely available. The study was approved by the Kruskal-Wallis and followed by Mann-Whitney U. The p-value 0.05 or Ethical Committee for Animal Experiments of the University of Kuopio. less was used as the level of statistical significance. The behavioral activity data are presented as number of animals being active at each minute. The Experiments differences between carbamate-treated and control groups were tested using chi-square test. Comparison of physostigmine and eptastigmine. Physostigmine (0.09 mg/kg in volume of approximately 0.2 ml saline; 1.64 mM), or eptastigmine (1.5 mg/kg in volume of approximately 0.2 ml saline; 20.9 mM), or saline
RESULTS
were injected into the tail vein. Immediately after the administrations, the animals were placed into cages in groups of two or three (n Å 5/group).
Eptastigmine (1.5 mg/kg) inhibited the plasma BChE acThe groups to be studied for 2 and 4 hr were video recorded for 2 hr. The tivity almost totally during the first 10 min, but the activity number of animals being active with or without locomotion were recorded from the videotape once per minute. At the time points of 10 min, 2, 4, 6, recovered to the control level within 6 hr ( Table 1 ). The and 24 hr the animals were sacrificed by carbon dioxide; blood samples physostigmine-inhibited activity had also recovered close (approximately 1.0 ml) were drawn by cardiac puncture into heparinized to the control level within 6 hr. The blood AChE activity, tubes. The 25 ml of blood were diluted with 20 volumes of 0.1% Triton in illustrating the AChE activity in erythrocytes, was slower 50-mM sodium phosphate buffer. After that the brains were, quickly disand less inhibited by eptastigmine than the plasma BChEs.
sected, and immediately frozen on dry ice. Plasma was separated with a hematocrit centrifuge at 1000g for 10 min at 4ЊC. The samples were stored Eptastigmine administration inhibited the blood AChE activat 075ЊC until analyzed.
ity only by 20% in 10 min and the maximum inhibition Effect of eptastigmine-phosphotriesterase combination. Eptastigmine (30%) was seen 2 hr after the administration. The AChE (0.9 mg/kg in volume of approximately 0.2 ml saline; 12.5 mM) was injected activity in brain was immediately maximally inhibited by into the tail vein 10 min prior to the ip injection of DFP (1.75 mg/kg in eptastigmine, but the activity had recovered totally by 24
volume of approximately 0.5 ml olive oil). Phosphotriesterase (83 U and 6.9 mg/g body weight in volume of approximately 0.2 ml) was injected iv hr. The effect of physostigmine on the enzyme activities in 10 min after DFP. The control animals received saline and/or olive oil. To erythrocytes and brain was shorter than that of eptastigmine.
avoid possible signs of poisoning the mice received sc atropine (37.5 The behavioral activity of eptastigmine-treated animals mg/kg in a volume of approximately 0.15 ml saline) immediately after the seemed to be slightly reduced between 10-25 min (Fig. 1) .
OP injection. At 1, 3, 6, and 24 hr after the DFP exposure, the mice were However, the differences between eptastigmine and control sacrificed by carbon dioxide and blood samples (approximately 1.0 ml) were drawn by cardiac puncture into heparinized tubes. Blood, brain, and groups were only occasionally significant. In contrast, the lung were removed, dissected, handled, and frozen as above.
activity of mice treated with physostigmine was rapidly though transiently reduced. This effect lasted for 26 min,
Assay of ChE Activities
after which there were no notable differences between the ChE activities were measured spectrophotometrically at 410 nm at 37ЊC groups.
with the method of Ellman et al. (1961) using acetylthiocholine iodide as
The half-life of phosphotriesterase was 4 -5 hr in the the substrate for brain and lung and butyrylthiocholine iodide for plasma. mouse circulation (data not shown). Phosphotriesterase AChE activity in the blood was measured using propionylthiocholine iodide as the substrate according to the method of Augustinsson et al. (1978) . (83 U/g bw) protected both the blood AChE and the AChE activity was measured after the inhibition of BChE with a specific plasma BChE activities against DFP inhibition ( Fig. 2A inhibitor Astra 1397-HCl. The blood samples were preincubated with Astra-and B). The combined eptastigmine -phosphotriesterase compound for 2 min before addition of the substrate.
treatment of mice did not increase the DFP-inhibited

Assay of Plasma CaE Activity
AChE activities until 24 hr after the exposure (Fig. 2A) . The eptastigmine -phosphotriesterase combination clearly CaE activity was measured from plasma samples according to the method of Zemaitis and Greene (1976) using 0.02 M p-nitrophenylacetate as the improved, however, the protection of plasma BChE com- pared with phosphotriesterase treatment alone (Fig. 2B) . this time. At 24 hr, the enzyme activity had also spontaneously recovered to 60% of the control. The activity was DFP inhibited by 90% the plasma BChE activity within the first hour, from which the activity recovered spontane-slightly increased by eptastigmine-phosphotriesterase treatment. Compared with the plasma BChE, CaE activity ously to about 30% at times between 6 and 24 hr. The phosphotriesterase treatment alone slightly protected this seemed to be less inhibited.
Phosphotriesterase administration effectively protected activity during the first 6 hr. On the other hand, in eptastigmine -phosphotriesterase-treated mice the activity of this the brain AChE activity against the DFP-induced inactivation (Fig. 2C) . Eptastigmine inhibited the brain AChE activenzyme was inhibited only by 55% at 1 hr, and it had recovered almost to the normal level by 24 hr.
ity by 45% in the first hour, and the activity returned to the 90% of control within 24 hr. The eptastigmine-phosphoBoth the phosphotriesterase and the eptastigmine-phosphotriesterase treatments increased the plasma CaE activities triesterase combination also protected the enzyme activity against DFP. However, phosphotriesterase alone provided measured at 6 hr after DFP exposure in mice (Fig. 3) . In untreated mice, the activity had also partly recovered during better protection for the brain enzymes at the 6-hr assessment. Twenty-four hours after the treatment, the activity was at the same level in both treatment groups. Phosphotriesterase did not prevent the inhibition of lung AChE activity during the first hour. After that, however, it assisted the recovery of activity up to 6 hr. Twenty-four hours after the DFP exposure there was no difference in the activity between the DFP and DFP -phosphotriesterase treatments (Fig. 2D) . The eptastigmine treatment reduced the activity more than DFP. The combination of eptastigmine with phosphotriesterase did not provide any additional protection for the enzyme during the first 6 hr. After 24 hr, however, there was a clear difference between the groups. The enzyme activity had recovered to normal in the eptastigmine -phosphotriesterase group, whereas in mice receiving only phosphotriesterase the activities were still inhibited by 25%. proved to be more effective against DFP exposure in plasma,
In lung, eptastigmine-phosphotriesterase administration where the BChE activity had recovered somewhat already decreased the AChE activity at first more than DFP. After within 1 hour. It seems likely that, phosphotriesterase could 6 hr, however, the activity was at the same level as in phosmore effectively hydrolyze DFP in plasma when eptastig-photriesterase-treated animals. After 24 hr, the activity had mine prevented its binding to BChEs. When eptastigmine recovered to the normal level with the combined eptastigwas released from the BChEs, the concentration of DFP was mine-phosphotriesterase treatment. Interestingly, in the too low to inhibit the enzymes. The DFP inhibition of plasma lungs of animals treated with eptastigmine only, the activity CaE was also partly prevented by phosphotriesterase. Eptas-remained lower than with the eptastigmine-phosphotriestertigmine-phosphotriesterase combination did not increase ase combination. In brain and erythrocytes, the protective these activities. effect of phosphotriesterase was so great that eptastigmine could not supplement it further. Physostigmine and its heptyl derivative eptastigmine are able to penetrate the blood -brain barrier and protect brain enzymes against OPs. Eptastigmine has greater lipophilicity and a longer duration of action than physostigmine (Marta et al., 1988; Sramek et al., 1995; Unni et al., 1994) . The longer duration of action may be due to the greater molecular size of eptastigmine (C 21 H 33 N 3 O 2 vs C 15 H 21 N 3 O 2 ). In the brain of rats, the reactivation time is approximately 20 min for physostigmine, while for eptastigmine it is seven times longer (Marta et al., 1988) . Unni et al. (1993) suggested that the eptastigmine- inhibited  FIG. 3 . The effect of iv phosphotriesterase (PTE) (approximately 83 erythrocyte AChE would be a peripheral marker for AChE U/g bw) and/or heptylphysostigmine tartrate (EPTA) (0.90 mg/kg) on inhibition in the brain. According to our results both enplasma CaE activities in mice. Control activity was 3843 { 324 nmol/min 1 ml. Means { SD are given, n Å 3-5. For explanations see Fig. 2 . zymes had recovered nearly to normal within 24 hr. The maximal inhibition, however, was greater and faster in of phosphotriesterase was already seen after 1 hr in the re
